Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies

[1]  Xuelin Huang,et al.  A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. , 2018, Blood.

[2]  C. Nabhan,et al.  Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study , 2018, British journal of haematology.

[3]  A. Gupta,et al.  Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status , 2018, Clinical pharmacology and therapeutics.

[4]  G. Follows,et al.  OUTCOMES OF PATIENTS POST IBRUTINIB TREATMENT FOR RELAPSED/REFRACTORY CLL: A UK AND IRELAND ANALYSIS , 2017 .

[5]  J. Schellens,et al.  Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients , 2017, Clinical Pharmacokinetics.

[6]  V. Gandhi,et al.  Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes , 2016, Leukemia.

[7]  N. Chiorazzi,et al.  BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia , 2015, Leukemia.

[8]  Mitchell R. Smith.  Ibrutinib in B lymphoid malignancies , 2015, Expert opinion on pharmacotherapy.

[9]  J. Murphy,et al.  Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants , 2015, Pharmacology research & perspectives.

[10]  L. Leclercq,et al.  Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men , 2015, Drug Metabolism and Disposition.

[11]  J. Beijnen,et al.  Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. , 2014, British journal of clinical pharmacology.

[12]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[13]  J. Byrd,et al.  The B-cell receptor signaling pathway as a therapeutic target in CLL. , 2012, Blood.

[14]  C. Geest,et al.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.

[15]  N. Chiorazzi,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.

[16]  France Mentré,et al.  Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model , 2011, The AAPS Journal.

[17]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[18]  U. Fuhr,et al.  Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers , 2010, Clinical pharmacology and therapeutics.

[19]  J. Goldstein,et al.  Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. , 2005, Pharmacogenomics.

[20]  Mats O Karlsson,et al.  Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. , 2003, British journal of clinical pharmacology.

[21]  B. Meibohm,et al.  The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients , 2003, Journal of clinical pharmacology.

[22]  H. Niiro,et al.  Decision making in the immune system: Regulation of B-cell fate by antigen-receptor signals , 2002, Nature Reviews Immunology.

[23]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[24]  Xavier Woot de Trixhe,et al.  Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies , 2014, Cancer Chemotherapy and Pharmacology.

[25]  Anna Tostevin,et al.  An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP) , 2014 .

[26]  V. Haufroid,et al.  CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.

[27]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION , 2007 .